与ADCY5相关的动力障碍 - 病例系列与文献综述
Katarzyna Kozon1, Weronika Łysikowska1, Jakub Olszewski1
1Student Scientific Group, Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland.
Neurologia i neurochirurgia polska
|January 17, 2024
概括
与ADCY5相关的动力障碍,是一种罕见的神经疾病,呈现出异质的症状,如 dystonia 和chorea. 基因诊断对于识别这种疾病和为潜在的向治疗铺平道路至关重要.
科学领域:
- 神经学 神经学
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 与ADCY5相关的动力障碍是一种罕见的遗传神经系统疾病.
- 由腺环酶5 (ADCY5) 基因的突变引起,影响细胞内信号传递.
- 表现在临床上是异质的,包括动力障碍,胆发病和 dystonia,治疗选择有限.
研究的目的:
- 要总结最近关于ADCY5相关神经系统疾病的文献.
- 介绍一个波兰家庭ADCY5突变的案例研究.
- 突出基因诊断对未来治疗策略的重要性.
主要方法:
- 从2017年1月到2022年1月,对ADCY5相关的运动障碍病例的文献综述.
- 分析症状频率和临床表现.
- 一个家族发生的症状ADCY5相关的动力障碍病例报告.
主要成果:
- 在文献中确定了52名患有ADCY5相关动力障碍的人.
- 在50%以上的患者中, dystonia 是最常见的症状,其次是动力障碍和胆.
- 一个家族病例证明了与ADCY5相关的症状性运动障碍的遗传模式.
结论:
- ADCY5突变会导致一系列的神经症状,其中最常见的是 dystonia.
- 早期遗传诊断对于了解ADCY5相关的动力障碍至关重要.
- 基因洞察对于开发针对性治疗这种罕见疾病至关重要.
相关概念视频
01:24Parkinson's Disease: Treatment
272
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
272
01:15Parkinson's Disease: Overview
551
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
551